Stockscreener 앱 받기
20.77
3.54%
0.71
시간 외 거래:
20.93
0.16
+0.77%
전일 마감가:
$20.06
열려 있는:
$19.87
하루 거래량:
69,221
Relative Volume:
0.61
시가총액:
$484.09M
수익:
$36,000
순이익/손실:
$-274.45M
주가수익비율:
-1.7586
EPS:
-11.8105
순현금흐름:
$-150.80M
1주 성능:
-16.17%
1개월 성능:
-3.84%
6개월 성능:
+58.67%
1년 성능:
+78.50%
1일 변동 폭
$19.80
$21.06
1주일 범위
$18.90
$25.48
52주 변동 폭
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
명칭
Lyell Immunopharma Inc
전화
650 695-0677
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
20.77 | 467.54M | 36,000 | -274.45M | -150.80M | -11.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 개시 | Citizens | Mkt Outperform |
| 2025-12-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-06-27 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-11-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-17 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | BofA Securities | Buy |
| 2021-07-12 | 개시 | Goldman | Buy |
| 2021-07-12 | 개시 | JP Morgan | Overweight |
| 2021-07-12 | 개시 | Morgan Stanley | Overweight |
모두보기
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Is Lyell Immunopharma Inc impacted by rising rates2026 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Lyell Immunopharma (LYEL) grants CFO 140,000 stock options - Stock Titan
Lyell Immunopharma (LYEL) CFO Shah identified as insider in Form 3 - Stock Titan
Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC - MarketBeat
Citizens reiterates Lyell Immunopharma stock rating on trial progress By Investing.com - Investing.com Canada
Lyell Immunopharma closes $50M equity tranche, names new CFO By Investing.com - Investing.com Nigeria
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - MarketBeat
Lyell Immunopharma: Q4 Earnings Snapshot - theheraldreview.com
Lyell Immunopharma 2025 Annual Report: Advancing Next-Generation CAR T-Cell Therapies for Cancer Treatment - Minichart
Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4MNews and Statistics - IndexBox
Lyell Immunopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Misses Expectations By $5.53 EPS - MarketBeat
Lyell Immunopharma: Fourth Quarter Financial Results Overview - Bitget
Lyell Immunopharma misses Q4 revenue estimates - TradingView
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - The Manila Times
LYEL: Pivotal CAR T-cell trials show strong efficacy, with key data updates and solid funding ahead - TradingView
ARCH Venture funds add Lyell (LYEL) stake with 488,090-share buy - Stock Titan
ARCH Venture Fund XIII boosts Lyell (LYEL) stake with 488K-share purchase - Stock Titan
Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer Effective March 2026 - Minichart
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma, Inc. announced that it has received $99.999968 million in funding - marketscreener.com
Citizens Initiates Coverage on LYEL with Market Outperform Ratin - GuruFocus
Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Citizens Jmp - MarketBeat
Lyell Immunopharma (NASDAQ: LYEL) hires Smital Shah as finance chief - Stock Titan
Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026 - marketscreener.com
Cancer cell therapy milestone brings Lyell $50M cash boost and new CFO - Stock Titan
Citizens initiates Lyell Immunopharma stock at outperform, $34 target - Investing.com South Africa
Citizens initiates Lyell Immunopharma stock at outperform, $34 target By Investing.com - Investing.com Australia
Citizens Initiates Coverage of Lyell Immunopharma (LYEL) with Market Outperform Recommendation - MSN
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation - MSN
Take Profit: Will Lyell Immunopharma Inc benefit from rate cutsTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Fund Flows: Is Lyell Immunopharma Inc impacted by rising ratesIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Breakouts Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Weekly Recap & Long-Term Capital Growth Ideas - baoquankhu1.vn
Lyell Immunopharma Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView
Lyell Immunopharma (LYEL) to Release Earnings on Tuesday - MarketBeat
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know - TipRanks
LYEL.O Technical Analysis & Stock Price Forecast - Intellectia AI
LYEL Technical Analysis & ETF Price Forecast - Intellectia AI
Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewswire
What is the long term forecast for Lyell Immunopharma Inc. stockEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
How Lyell Immunopharma Inc. stock reacts to global recession fearsPortfolio Risk Report & Weekly Return Optimization Plans - mfd.ru
What’s the MACD signal for Lyell Immunopharma Inc.Portfolio Value Summary & Free Verified High Yield Trade Plans - mfd.ru
Is Lyell Immunopharma Inc. stock gaining market shareWeekly Trend Recap & Stock Market Timing Techniques - mfd.ru
Can Lyell Immunopharma Inc. stock beat market expectations this quarterJuly 2025 Movers & Reliable Intraday Trade Alerts - mfd.ru
Will Lyell Immunopharma Inc. stock deliver shareholder valueMarket Trend Review & Fast Gaining Stock Strategy Reports - mfd.ru
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap DownHere's Why - MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Up 28.0% in January - MarketBeat
Can Lyell Immunopharma Inc. maintain sales growthJuly 2025 Outlook & Fast Moving Stock Trade Plans - mfd.ru
Institution Moves: Can Lyell Immunopharma Inc maintain sales growth2025 Retail Activity & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
LYEL Should I Buy - Intellectia AI
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs - BioPharma Dive
Lyell Immunopharma Inc (LYEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):